Every night, the online Belgian patent register ('eRegister') receives an update with public data that were entered or generated the preceding day on the Benelux Patent Platform, the computer application with which the Belgian Intellectual Property Office handles the registration, treatment and publication processes for patents and supplementary protection certificates.
Currently, some updates are spread over consecutive nights due to the large, weekly volume of data concerning European patents designating Belgium.
For a European patent it is possible that data about the inventor(s) are missing from the online Belgian patent register. They can be found via the link to the European patent register pending an update of the Belgian patent register.
For European patents with Unitary Effect, the authentic source of information is the European Patent Register : please refer to it.

Patent details

2013C060 Product name: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOÏNE

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic information

Application number:
2013C/060
Type:
Certificate
SPC type:
Medical
Basic patent number:
019572387
Status:
Active
Publication number:
2013C060
1rst applicant's nationality:
Procedural language:
Dutch

Marketing authorization

Marketing authorization number:
BE437507
Marketing authorization type:
National/EU
Designates country:
No
Marketing authorization date:
06/05/2013
Marketing authorization status:
Accepted
Marketing authorization country:
Belgium (BE)

Dates

Filing date:
30/10/2013
First marketing authorization date:
06/05/2013
Grant date:
15/12/2020
Activation date:
24/07/2021
BE Publication date:
06/06/2018
Lapsed date:
Expiration date (if granted and all annual fees paid):
Basic SPC Expiration (if granted and all annual fees paid):
24/07/2026
SPC/SPC Extension Expiration (if granted and all annual fees paid):
24/07/2026
Rejection date:
Withdrawal date:

Applicant

Name:
Dow Pharmaceutical Sciences, Inc.
Legal Form:
From:
30/10/2013
Address:
1330a Redwood Way, Petaluma CA-94954-6542, United States (US)
To:

Agent

Name:
OSTYN Frans
Legal Form:
From:
30/10/2013
Address:
Pres. Kennedypark 31c, 8500, KORTRIJK, Belgium (BE)
To:

Publication

Bulletin

1

Bulletin heading:
SPC
Journal edition number:
2018/14
Publication date:
22/08/2018
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates

2

Bulletin heading:
SPC
Journal edition number:
2020/30
Publication date:
10/02/2021
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates

3

Bulletin heading:
SPC
Journal edition number:
2021/14
Publication date:
18/08/2021
Description:
Contains data concerning applications for- or granted Supplementary Protection Certificates

Annual fee

Annual fee(s) Due Date:
Annual fee number:
Expected payer:
Last annual fee payment date:
07/05/2025
Last annual fee paid number:
25
Last annual fee paid amount:
850 Euro
Payer:
DENNEMEYER & Co S.A.R.L.
Filing date Document type Publication Type Document Description Number of pages File Type
15/12/2020 Publication I2 1 PDF /0/6/0/3/1/0300013060/docs/2013c060_0_i2document_20201215_111744276.pdf
06/06/2018 Publication I1 1 PDF /0/6/0/3/1/0300013060/docs/2013c060_1_i1document_20180606_145224591.pdf
15/12/2020 Outgoing Correspondence 2 PDF /0/6/0/3/1/0300013060/docs/2013c060_2_outgoingcorrespondence_20210201_040652957.pdf
15/12/2020 Certificate 2 PDF /0/6/0/3/1/0300013060/docs/2013c060_3_spc_medcertificate_20201215_111745397.pdf